Skip to content Skip to navigation

余书勤

余书勤教授生物学(生理学专业)研究生导师。药学(微生物与生化制药专业)研究生导师。

研究方向:以细胞膜上p-糖蛋白(p-gp)为切入点,围绕它的表达、细胞膜定位、线粒体功能、p-gp-ATP酶的相互作用,对抗癌药物与环境内分泌干扰物(EDCs)的吸收、分布与毒性进行探讨。以此为基础,主要在两个方向进行研究。在药学领域,研究方向为逆转癌症多药耐药(Multidrug resistance, MDR)的新型纳米递药系统(Nano-drug delivery system, NDDS)的生物效应与机理研究。在抗癌药物的靶向与共递药、细胞核递药以及MDR细胞内精准药物释放与逆转MDR方面进行探讨。在毒理学领域,对食品乳化剂与肠道微生物互作影响EDCs的吸收、毒性靶器官分布与毒效机理方面进行探讨。

科研成果:2011年以来,以通讯作者发表21SCI学术榜论著,包括11TOP论文。单篇最高IF 8.097(发表时5.93)。1 ESI热点与高被引论文,1ESI高被引论文。获得8项与新药有关的发明专利,其中3 项国际专利公开PCT。参与2 项新药研发被批准临床研究。

科研项目:作为负责人主持国家自然科学基金一项(在研)。作为子题负责人参与国家科技重大专项(新药创制)项目一项(完成)。

研究生培养:毕业人数30人。近5 年来,其中1人获得国家奖学金。 2 人获得江苏省优秀硕士研究生论文 (2015年度,2016年度)4 人获得朱敬文奖学金, 3人获得校级优秀研究生毕业论文奖,7人次获得优秀毕业研究生。研究生毕业后多在大型制药公司与药物研发公司, 或高级中学工作。目前在培研究生7人。

学术链接:作者:ORCID:0000-0002-2824-4651ResearcherID: K-5982-2012ScopusID55741364600。审稿人:Publons1225510/

联系方式:通讯地址江苏省南京市栖霞区文苑路1号,南京师范大学生命科学学院(210046)电话13805178158; Emailyushuqin@njnu.edu.cn

科研成果2011-

论著(仅列入作为通讯作者的论文,IF与分区为发表时)

  1. Shan-Shan Qi, Ling-Yuan Guo, Shu-Zhen Yan, Robert J. Lee, Shu-Qin Yu*, Shuang-Lin Chen*.Hypocrellin A-based photodynamic action induces apoptosis in A549 cells through ROS-mediated mitochondrial signaling pathway. ActaPharmaceuticaSinicaBdoi.org/10.1016/j.apsb.2018.12.004SCI, TOP, IF=6.014
  2. Jia-Hui Sun, Chong Ye, En-He Bai, Ling-Ling Zhang, Shao-JieHuo, Hao-Han Yu, Su-Yun Xiang*, Shu-Qin Yu*. Co-delivery nanoparticles of doxorubicin and chloroquine for improving the anti-cancer effect in vitro. Nanotechnology 2019;30(8):85101 SCI, TOP, IF=3.404
  3. Hai-TaoGao, RunXu, Wei-XinCao, Qian-NanDi, Rui-XianLi,LingengLu, QianXu, Shu-Qin Yu*.Combined effects of simultaneous exposure to six phthalates and emulsifier glycerol monosterate on male reproductive system in rats. Toxicology and Applied Pharmacology 341:2018, 87–97SCI, IF=3.616
  4. Shan-Shan Qi, Jia-Hui Sun, Hao-Han Yu, Shu-Qin Yu*. Co-delivery nanoparticles of anti-cancer drugs forimproving chemotherapy efficacy.Drug Delivery. 2017; 24(1)1909-1926SCI, TOP, IF=6.40
  5. Xi Lin, Shun-Zhen Yan, Shan-Shan Qi, QiaoXu, Shuang-Shuang Han, Ling-Yuan Gu, Ning Zhao, Shuang-Lin Chen*,Shu-Qin Yu*. Transferrin-Modified Nanoparticles for Photodynamic Therapy Enhance the Antitumor Efficacy of Hypocrellin A. Frontiers in Pharmacology.2017;8:0815SCI,IF=4.40
  6. Ling-Yuan Guo, Shu-Zhen Yan,  Qiang Li,  QiaoXu,  Xi Lin, Shan-Shan Qi, Shu-Qin Yu*, Shuang-Lin Chen*. Poly(lactic-co-glycolic) acid nanoparticles improve oral bioavailability of hypocrellin A in rat. RSC Advances.2017; 7: 42073-42082 SCI, IF=3.15
  7. Dan-Dan Zhang, Yan-Yan Kong, Jia-Hui Sun, Shao-JieHuo, Min Zhou, Yi-Ling Gui, Shu-Qin Yu*, QianXu*. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. International Journal of Nanomedicine.2017;12:20181-2108 SCI, TOP, IF=4.30
  8. Hai-Tao Gao, Run Xu, Wei-Xin Cao, Liang-Liang Qian, Min Wang, Lingeng Lu, QianXu*,Shu-Qin Yu*, Effects of six priority controlled phthalate esters with long-term low-dose integrated exposure on male reproductive toxicity in rats. Food and Chemical Toxicology. 2017;101:94-104SCI, TOP, IF=3.584】【ESI热点论文/ ESI高被引论文】
  9. Ying-Ying Wang, Dan-Dan Zhang, Yan-Yan Kong, Luan-Luan Shao, Fen-Yi Zhang, Yu Gao, Xu Mu, Jie Wang, Hao-Fan Li, Shu-Qin Yu*, QianXu*. CS/PAA@TPGS/PLGA nanoparticles with intracellular pH-sensitivesequential release for delivering drug to the nucleus of MDR cells. Colloids and Surfaces B: Biointerfaces. 2016; 145:716-727SCI, IF=4.12
  10. Wang Dong-Fang, Rong Wen-Ting, Lu Yu, HouJie, Qi Shan-Shan, Xiao Qing, Zhang Jue, You Jin,Shu-QinYu*, XuQian*. TPGS2k/PLGA nanoparticles for overcoming multidrug resistance by interfering mitochondria of human alveolar adenocarcinoma cells. ACS Applied Materials & Interfaces.2015; 7(7): 3888-3901 SCI, TOP, IF=5.93 
  11. Lu Yu, Wang Ying-Ying, Yang Nan, Zhang Dan, Zhang Feng-Yi, GaoHai-Tao, Rong Wen-Ting, Shu-Qin Yu*, XuQian. Food emulsifier polysorbate 80 increases intestinal absorption of di-(2-ethylhexyl) phthalate in rats.Toxicological Sciences.2014: 139 (2): 317-327SCI, IF=4.50
  12. Rong Wen-Ting, Lu Ya-Peng, Tao Qing, Guo Miao, Lu Yu, RenYong , Shu-Qin Yu*.Hydroxypropyl-sulfobutyl-β-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes. Journal of Pharmaceutical Sciences. 2014; 103(2): 730-742 SCI, IF=3.3
  13. Qi Shan-Shan, Lin Xi, Zhang Miao-Miao, Yan Shu-Zhen, Shu-Qin Yu*, Chen Shuang-Lin*.  Preparation and evaluation of hypocrellin A loaded poly(lactic-co-glycolic acid) nanoparticles for photodynamic therapy. RSC Advances.2014; 4 (75): 40085-40094  SCI, IF=3.8
  14. Ya-Peng Lu, Si-Yuan Liu, Yu Zhao, Li Zhu*, Shu-Qin Yu*. Complexation of Z-ligustilide with hydroxypropyl-b-cyclodextrin to improve stability and oral bioavailability. Acta Pharmaceutica.2014; 64:211-222 SCI, IF=1.0
  15. Guo Miao, Rong Wen-Ting, HouJie, Wang Dong-Fang, Lu Yu, Wang Ying,Shu-Qin Yu*, XuQian*.  Mechanisms on chitosan-coated poly (lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin. Nanotechnology. 2013; 24: 245101 (15pp) SCI, TOP, IF=3.90
  16. Wang Ying, Guo Miao, Lu Yu, Ding Li-Ying, Ron Wen-Ting, Liu Ya-Qing, Song Fei-Fei, Shu-Qin Yu*. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. Nanotechnology.2012; 23:495103 (14pp) SCI, TOP, IF=3.90
  17. Chen Cheng, Xie Xiao-Xia, Zhou Qian, Zhang Feng-Yi, Wang Qiao-Lin, Liu Ya-Qing, Zou Yi-Na, Tao Qing, JiXue-Mei, Shu-Qin Yu*. EGF-functionalized single-walled carbon nanotubes for targeting delivery of etoposide. Nanotechnology. 2012; 23: 045104 (12pp) SCI, TOP, IF=3.90
  18. XuQian, Wang Min, Shu-Qin Yu*, Tao Qing, Tang Meng*. Trace analysis of diethylstilbestrol, dienestrol and hexestrol in environmental water by Nylon 6 nanofibers mat-based solid-phase extraction coupled with liquid chromatography-mass spectrometry. Analyst.2011; 136 (23): 5030-5037 SCI, IF=3.90
  19. Huang Xing-Xing, Zhou Cheng-Liang, Wang Hui, Chen Cheng, Shu-Qin Yu*, XuQian, Zhu Yin-Yan, Ren Yong. Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-beta-cyclodextrin inclusion complex. AAPS PharmSciTech. 2011; 12(2): 665-672 SCI, IF=1.24
  20. Xie Xiao-Xia, Tao Qing, Zou Yi-Na, Zhang Feng-Yi, Guo Miao, Wang Ying, Wang Hui, Zhou Qian, Shu-Qin Yu*. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms.Journal of Agricultural and Food Chemistry. 2011; 59 (17): 9280-9289 SCI, TOP, IF=2.93】【ESI高被引论文】
  21. Wang Hui, Xie Xiao-Xia, Zhang Feng-Yi, Zhou Qian, Tao Qing, Zou Yi-Na, Chen Cheng, Shu-Qin Yu*. Evaluation of cholesterol depletion as a marker of nephrotoxicity in vitro for novel β-cyclodextrin derivatives. Food and Chemical Toxicology.2011; 49(6): 1387-1393SCI, TOP, IF=2.80

国际会议论文

  1. Ying Wang, Miao Guo, Yu Lu, LiYing Ding, Shu-Qin Yu*. PLGA nanoparticles containing SN-38 for reversing multiple drug resistance of A549/DDP Cells. Journal Control Release.2013; 172(1):e67
  2. Miao Guo, Ying Wang, Wen-Ting Rong, Li-ying Ding, Shu-Qin Yu*. Chitosan-modified PLGA nanoparticles as drug delivery carrier for modulating P-glycoprotein of enterocytes. Journal Control Release.2013; 172(1):e112-3

发明专利(国际专利公开 PCT

  1. Yong Ren,Xue-Qin Ma, Shu-Qin Yu, Xia-Dong-Sun.Hydroxypropyl-sulfobutyl-beta-cyclodextrin, the preparation method, the analytical method, and the pharmacutical application thereof. Patent No: US82784372B2, Application No: 12/092273, Publication Date: 20070510
  2. Yong Ren, Jing-FengGao, Shu-Qin Yu, Ling Wu. Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof, Patent No: US8426385B2, Application No: 12/440792, Publication date: 20130423
  3. Yong Ren, Jing-FengGao, Shu-Qin Yu, Ling Wu. Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process, Patent No: US8481511B2, Application No: 12/440942, Publication date: 20130709

科研项目:

  1. 主持:国家自然科学基金,非离子型食品乳化剂增加邻苯二甲酸酯类吸收的效应及机制研究 。批准号81673214
  2. 子题负责:国家科技重大专项(新药创制)项目,一类以CD11b为靶的抗白细胞-内皮细胞粘附乳糖衍生物候选药物研究。批准号2009ZX09103-44